samedan logo
 
 
 
spacer
home > ebr > summer 2002 > contract development - industry spend and value
PUBLICATIONS
European Biopharmaceutical Review

Contract Development - Industry Spend and Value

We have entered a period of growth in the drug development industry, driven largely by financial investment and an increase in validated targets. This expansion has created a competitive need for finite drug development resources. As an employee of a preclinical testing company, I will be drawing on my experiences to comment on the value of the contract research organisation (CRO) and the growth of contract research, explaining these in the context of the biopharmaceutical industry.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Benjamin Jones, Business Development Manager at Huntingdon Life Sciences Ltd
Dr Benjamin Jones has a bachelor's degree in Zoology from Nottingham University, and received his PhD from the Welsh School of Pharmacy at Cardiff University.
After a short academic career he joined Huntingdon Life Sciences (HLS) Business Development Group in early 2000. Ben has worked for Huntingdon in the US and the UK and is currently responsible for biopharmaceutical and inhalation toxicology business development.

spacer
Dr Benjamin Jones
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Datwyler Recognized as Pivotal Partner for COVID-19 Vaccine Providers

Altdorf, Switzerland, 10, June 2021 — Datwyler, a leading provider of high-quality, system-critical elastomer components, was recognized by BioNTech among its partners in supporting the company to provide a vaccine for COVID-19. Datwyler is also a supplier to the Serum Institute of India. Since the onset of the coronavirus, Datwyler has supplied system-critical packaging components for injectable drugs such as stoppers and aluminum seals to vaccine developers around the world. “It is an honor to be recognized for our role in supporting the leading pharmaceutical companies of the world in their fight to combat this global pandemic,” said Dirk Lambrecht, CEO of Datwyler.
More info >>

White Papers

Customising the Cold Chain

World Courier

Of all the statistics emerging around the global pharmaceutical industry this year, two big numbers capture the attention of both manufacturers and their logistics partners: $248 billion, the amount the “BRIC” nations (Brazil, Russia, India and China) are poised to account for in pharmaceutical sales for by 2016; and $8 billion, the amount global pharma will spend on cold chain logistics in 2014. Why are these two numbers so noteworthy? They demonstrate that as R&D goes, so goes logistics. As products evolve to meet demands for more targeted therapies, demand for more targeted logistics solutions grows as well. And that means a need for customization for everything from clinical trial samples to finished product.
More info >>

 
Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement